Genomic Health, Inc. (GHDX) COO G Bradley Cole Sells 5,000 Shares

Genomic Health, Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $29.94, for a total value of $149,700.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, November 7th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $31.47, for a total transaction of $157,350.00.
  • On Tuesday, October 10th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $31.93, for a total transaction of $159,650.00.

Shares of Genomic Health, Inc. (NASDAQ:GHDX) traded down $2.05 during midday trading on Wednesday, reaching $28.00. 455,882 shares of the company’s stock were exchanged, compared to its average volume of 118,663. Genomic Health, Inc. has a 1 year low of $26.37 and a 1 year high of $34.02.

A number of hedge funds and other institutional investors have recently modified their holdings of GHDX. Vanguard Group Inc. lifted its holdings in Genomic Health by 6.8% in the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock worth $54,379,000 after acquiring an additional 106,452 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Genomic Health by 10.9% in the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock worth $26,473,000 after acquiring an additional 80,100 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Genomic Health by 26.1% in the second quarter. Goldman Sachs Group Inc. now owns 370,806 shares of the medical research company’s stock worth $12,070,000 after acquiring an additional 76,758 shares during the last quarter. Citadel Advisors LLC lifted its holdings in Genomic Health by 269.5% in the third quarter. Citadel Advisors LLC now owns 93,803 shares of the medical research company’s stock worth $3,010,000 after acquiring an additional 68,418 shares during the last quarter. Finally, Cowen Prime Services LLC lifted its holdings in Genomic Health by 324.1% in the second quarter. Cowen Prime Services LLC now owns 88,635 shares of the medical research company’s stock worth $2,885,000 after acquiring an additional 67,735 shares during the last quarter. 89.76% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently commented on the stock. Jefferies Group reaffirmed a “hold” rating and set a $34.00 price target on shares of Genomic Health in a research report on Friday, October 20th. Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. Cowen reaffirmed a “hold” rating and set a $34.00 price target on shares of Genomic Health in a research report on Friday, September 1st. Canaccord Genuity reaffirmed a “buy” rating and set a $35.00 price target on shares of Genomic Health in a research report on Wednesday, September 27th. Finally, BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $31.57.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/13/genomic-health-inc-ghdx-coo-g-bradley-cole-sells-5000-shares.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply